Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
ULESFIA is a topical lotion approved in 2009 for a dermatological indication, though the specific mechanism of action and therapeutic target are not publicly detailed in available data. It is a small molecule topical formulation developed and marketed by Shionogi. The product is currently approaching loss of exclusivity, indicating it has moved through its commercial lifecycle.
As LOE approaches, the commercial team is likely focused on lifecycle extension strategies and managing competitive pressure (score: 30/100), with smaller team footprint expected post-LOE.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
ULESFIA supports 43 linked job opportunities, predominantly in Quality Assurance, IT, Commercial, and Legal—reflecting a mature product requiring operational and compliance focus rather than clinical innovation. Working on ULESFIA offers roles in manufacturing excellence, commercial optimization, and regulatory compliance, but limited growth potential given its LOE-approaching status.
Worked on ULESFIA at Shionogi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
43 open roles linked to this drug